Table 2:

Clinicopathologic characteristics at tertiary cytoreduction (N=114)

Variable	n (%)
Age at tertiary cytoreduction, years
Median (range)	57.5 (30.0-83.0)
Treatment-free interval, months
Median (range)	16.1 (0.36-152.8)
Time from secondary cytoreduction, months
Median (range)	24.7 (5.6-111.3)
Platinum sensitivity
Sensitive	101 (88.6%)
Resistant	13 (11.4%)
CA-125 at tertiary cytoreduction, U/mL (n=89)
Median (range)	31 (4.0-2475.0)
Preoperative imaging (n=107)
CT	70 (65.4%)
PET-CT	33 (47.1%)
MRI	4 (5.7%)
Sites of recurrence on imaging (n=107)
1 site	56 (52.3%)
2 sites	31 (29.0%)
3 or more sites	20 (18.7%)
Residual disease at tertiary cytoreduction
CGR	102 (89.5%)
Residual disease	12 (10.5%)
Sites of recurrence (n=106)
Median (range)	2 (1-10)
Sites of recurrence
Single	51 (44.7%)
Multiple	63 (55.3%)
Surgical procedure performed
Open non-visceral resection (abdominopelvic)	24 (21.1%)
MIS non-visceral resection (abdominopelvic)	1 (0.9%)
Large bowel resection	32 (28.1%)
Small bowel resection	16 (14.0%)
Partial liver resection	12 (10.5%)
Open pelvic and/or paraaortic lymph node resection	20 (17.5%)
MIS pelvic and/or paraaortic lymph node resection	3 (2.6%)
Inguinal lymph node resection	4 (3.5%)
Diaphragm resection	7 (6.1%)
Open visceral resection (spleen, pancreas, adrenal, kidney)	11 (9.6%)
MIS visceral resection (spleen)	1 (0.9%)
Cardiothoracic resection (supradiaphragmatic/cardiophrenic/mediastinal lymph nodes, lung)	6 (5.3%)
Adjuvant therapy after tertiary cytoreduction (n=113)
Cytotoxic	72 (63.7%)
Hormonal	12 (10.6%)
Radiation	12 (10.6%)
PARPi	2 (1.8%)
Observation	15 (13.3%)
Status at last follow-up
AWD	28 (24.6%)
NED	24 (21.1%)
DOD	60 (52.6%)
DOO	2 (1.8%)

CT, computed tomography; PET, positron emission tomography; MRI, magnetic resonance imaging; CGR, complete gross resection; MIS, minimally invasive surgery; PARPi, Poly (ADP-ribose) polymerase inhibition; AWD, alive with disease; NED, no evidence of disease; DOD, died of disease; DOO, died of other cause